Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer

International Journal of Medical Sciences

Volumn 5, Issue 2, 2008, Pages 100-105

  Dufresne, Armelle ^a   Pivot, Xavier ^b   Tournigand, Christophe ^c   Facchini, Thomas ^d   Alweeg, Thierry ^e   Chaigneau, Loic ^b   De Gramont, Aimery ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d Cancer Center   (France)

^e Anti Cancer Center   (France)

Author keywords

Breast cancer; Chemotherapy; Hormonotherapy; Maintenance treatment; Metastatic

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FULVESTRANT; HORMONE; MEGESTEROL ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; FEMALE; HORMONAL THERAPY; HUMAN; LIVER METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

EID: 45849130936     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.5.100     Document Type: Article

References (21)

1. Remontet L, Esteve J, Bouvier AM et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003;51(1 Pt 1):3-30
2. Dickson R, Pestell R, Lippman M. Metastatic breast cancer. In: DeVita T, Hellman S, Rosenberg S, eds. Cancer Principles and practice of oncology. 7 ed: Philadelphia : Lippincot company; 2005:1453-62
3. Ellis M, Hayes D, Lippman M. Treatment of metastatic breast cancer. In: Harris J, Lippman M, Morrow M, Osborne C, eds. Diseases of the breast. 2 ed. Philadelphia : Lippincot company; 2000:749-97.
4. Dufresne A, Pivot X, Tournigand C, Facchni T, Alweeegg T, Chaigneau L, De Gramon A. Impact of chemotherapy beyond the fisrt line in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2008; 107: 275-279
5. Clark G, Sledge G, Osborne C et al. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987; 5: 55-61
6. Rizzieri DA, Vredenburgh JJ, Jones R, et al. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 1999; 17(10): 3064-74
7. Nisman B, Barak V, Hubert A, et al. Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy. Anticancer Res 2003; 23(2C): 1939-42
8. Nomura Y. Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy. Int J Oncol 1998; 12(4): 817-24
9. Falkson G, Holcroft C, Gelman RS et al. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13(6): 1453-8
10. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Tap HY, Buzdar AU, Blumenschei GR. Multivariate analysis of prognostic factors in metasttaic breast cancer. J Clin Oncol 1983; 1(12): 776-86
11. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14(8):2197-205.
12. Pivot X, Asmar L, Buzdar A, Valero V, Hortobagyi GN. An unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 2000; 82: 529-34
13. Coates A, Gebsk V, Bishop JF at al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490-1495
14. Muss HB, Case LD, Richards F et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991; 325: 1342-1348
15. Falkson G, Gelman R, Pandya K et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998; 16 (5): 1669-1676
16. French Epirubicinn Study Group. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J Clin Oncol 2000; 18 (17): 3115-3124
17. Gregory RK, Powles TJ, Chang JC et al. A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 1997; 33 (13): 2194-2197
18. Nooi J M, de Haes J, Beex L et al. Continuing chemotherapy or not after the induction treatement in advanced breast cancer patients: clinical outcomes and oncologists' preferences. Eur J Cancer 2003; 39: 614-621
19. Kloke O, Klaasen U, Oberhoff C et al. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Essen Breast Cancer Study Group. Breast Cancer Res Treat 1999; 55 (1): 51-59
20. Berruti A, Zola P, Buniva T et al. Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival. Anticancer Res 1997; 17 (4A): 2763-2768
21. Montemurro F, Rondon G, Ueno NT et al. Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant 2002; 29 (10): 861-866